Vitruvias Therapeutics Issues Nationwide Recall for Thyroid Tablets Due to Potential Contamination
Vitruvias Therapeutics Inc. has issued a nationwide recall for one lot of Thyroid Tablets USP 30 mg due to potential contamination. The recall was announced by the FDA and reported by KSTP.com 5 Eyewitness News.
Minneapolis St. Paul, MN, August 26, 2026 —
Vitruvias Therapeutics Inc. has initiated a nationwide recall for a specific lot of its Thyroid Tablets USP 30 mg. The recall is a precautionary measure due to potential contamination concerns.
The U.S. Food and Drug Administration (FDA) announced the recall, which was also reported by KSTP.com 5 Eyewitness News. The specific lot number subject to the recall was not immediately available.
Thyroid hormone replacement therapy is crucial for individuals with hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones. These medications are essential for regulating metabolism, energy levels, and many other bodily functions. Contamination in such vital medications could pose significant health risks to patients.
The company has not released further details regarding the nature of the potential contamination or the specific risks associated with the affected lot. Patients who have received or are currently taking Thyroid Tablets USP 30 mg from Vitruvias Therapeutics Inc. are advised to check their medication packaging for lot information and to consult with their healthcare provider. The contractor’s name was not provided.
The FDA typically oversees drug recalls to ensure public safety. Information regarding the timeline of the recall, including when the issue was identified and reported, was not provided. The outcome of any subsequent inspections or the status of corrective actions taken by Vitruvias Therapeutics Inc. have not been detailed in the initial reports.
Consumers seeking more information about the recall are encouraged to contact Vitruvias Therapeutics Inc. or refer to announcements from the FDA. The fine amount, if any, was not specified.
Story summarized from the original created by Sabrina Salguero Del Cid on www.fda.gov, see more information here.
